Efficacy of Negative Pressure Wound Therapy Versus Conventional Moist Dressings on Diabetic Foot Ulcer Healing Trajectories

Completed · Not applicable

Conditions studied: Diabetic Foot Ulcer Healing Trajectories

In brief

Background: Diabetic foot ulcers (DFUs) are severe, chronic complications of diabetes carrying a high risk of amputation. While Negative Pressure Wound Therapy (NPWT) is an active biophysical treatment, clinical evidence using multidimensional tools in Middle Eastern settings like Jordan has been limited. Methods: A 3-month randomized controlled trial (January-May 2026) was conducted at the National Center for Diabetes, Endocrinology, and Genetics (NCDEG) in Amman, Jordan, involving 60 patients with chronic DFUs. Participants were randomized to either an intervention group receiving NPWT (80-125 mmHg, changed every 4 days) or a control group receiving conventional moist dressings (changed every 2 days). Wound trajectories were assessed using the 13-item Bates-Jensen Wound Assessment Tool (BWAT©).

Key facts

Study ID

NCT07745075

Run by

Jerash Private University

People needed

60

Starts

2026-01-01

Expected to finish

2026-05-01

Last updated by the study team

2026-08-04

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Aged 18 years or older.
• Diagnosed with superficial chronic diabetic foot ulcers (partial- or full-thickness) located on the plantar surface, metatarsal heads, or sole (Grade 1/clean ulcers). Had a wound length ranging from 10 to 15 cm. Had controlled diabetes mellitus with stable comorbid conditions (e.g., hypertension or non-end-stage renal disease).
• Were able to speak and read Arabic.
• Were able to perform activities of daily living (ADLs) independently.
• Provided voluntary written informed consent to participate in the study

You may not qualify if…

• Underlying osteomyelitis, Charcot's joint/arthropathy, or DFUs classified as Wagner Grade 3, 4, or 5.
• Severe peripheral vascular/arterial diseases, venous insufficiency, or bilateral involvement of both feet.
• Coagulopathic conditions, active bleeding tendencies, or severe immunocompromising diseases.
• Cognitive or mental impairments preventing informed participation.
• Severe diabetic complications (e.g., acute cerebrovascular disease).
• Pregnancy, active fever, or acutely infected wounds at baseline.

Where it is running

• the National Center for Diabetes, Endocrinology, and Genetics (NCDEG) — Amman, Dours, Jordan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.